Tomotherapy radiation treatment planning software gains FDA
clearance
9 February 2009
Swedish company RaySearch Laboratories AB (STO:RAYB) and TomoTherapy
Inc have announced that their jointly produced new software solution,
SharePlan, has received clearance by the FDA for market launch in the
US.
SharePlan is an advanced treatment planning solution that enables
transfer of treatment plans between TomoTherapy Hi-Art systems and
conventional linear accelerators. The product uses sophisticated
algorithms to automatically generate a selection of deliverable
high-quality IMRT plans based on an existing Hi-Art plan.
This time-saving concept is an important tool for optimizing patient
benefit and throughput at clinics that are introducing a Hi-Art system
into an environment with existing conventional linear accelerators.
“We put great pride in our collaboration with TomoTherapy and have
been working intensely on this product for little over a year, so of
course it feels very rewarding that we now reach the market. Automatic
plan generation is a revolutionary treatment planning concept that
offers unparalleled user-friendliness and has the potential to
dramatically reduce the everyday workload spent on routine tasks,” says
Johan Löf, President of RaySearch.
“Our success is not just based upon delivering the highest quality
radiation therapy,” according to Del Coufal, Vice President of Marketing
for TomoTherapy. “We understand how important it is for TomoTherapy
technology to seamlessly integrate into a cancer centre, regardless of
the type of surrounding equipment the centre also uses. By aligning with
industry-leading strategic partners like RaySearch, we are able to make
it easy for any centre to easily adopt our revolutionary radiotherapy
system.”
Bookmark this page